and Vermillion's stock offering. Read on… Arena Pharmaceuticals Inc. (ARNA) will be presenting data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate Ralinepag at the International Society …
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod …
Arena Pharmaceuticals, Inc. ARNA was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent …
Arena Pharmaceuticals, Inc. ARNA is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings …
Arena Pharmaceuticals, Inc. ARNA reported a loss of 86 cents per share in the third ... Arena’s shares were down almost 4% in after-hours trading. However, the stock has significantly outperformed the industry so far this year. While shares …